Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

668 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators. Opal S, et al. Among authors: francois b. Crit Care Med. 2004 Feb;32(2):332-41. doi: 10.1097/01.CCM.0000108867.87890.6D. Crit Care Med. 2004. PMID: 14758145 Clinical Trial.
Impact of obesity in mechanically ventilated patients: a prospective study.
Frat JP, Gissot V, Ragot S, Desachy A, Runge I, Lebert C, Robert R; Association des Réanimateurs du Centre-Ouest (ARCO) study group. Frat JP, et al. Intensive Care Med. 2008 Nov;34(11):1991-8. doi: 10.1007/s00134-008-1245-y. Epub 2008 Aug 1. Intensive Care Med. 2008. PMID: 18670754
Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial.
Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, LaRosa S, Wittebole X, Dhainaut JF, Doig C, Mendelson MH, Zwingelstein C, Su G, Opal S; CAPTIVATE Trial Group. Wunderink RG, et al. Among authors: francois b. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1561-8. doi: 10.1164/rccm.201007-1167OC. Epub 2011 Feb 4. Am J Respir Crit Care Med. 2011. PMID: 21297074 Clinical Trial.
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.
François B, Luyt CE, Dugard A, Wolff M, Diehl JL, Jaber S, Forel JM, Garot D, Kipnis E, Mebazaa A, Misset B, Andremont A, Ploy MC, Jacobs A, Yarranton G, Pearce T, Fagon JY, Chastre J. François B, et al. Crit Care Med. 2012 Aug;40(8):2320-6. doi: 10.1097/CCM.0b013e31825334f6. Crit Care Med. 2012. PMID: 22622405 Clinical Trial.
Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial.
Vignon P, Dequin PF, Renault A, Mathonnet A, Paleiron N, Imbert A, Chatellier D, Gissot V, Lhéritier G, Aboyans V, Prat G, Garot D, Boulain T, Diehl JL, Bressollette L, Delluc A, Lacut K; Clinical Research in Intensive Care and Sepsis Group (CRICS Group). Vignon P, et al. Intensive Care Med. 2013 May;39(5):872-80. doi: 10.1007/s00134-013-2814-2. Epub 2013 Jan 31. Intensive Care Med. 2013. PMID: 23370827 Clinical Trial.
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
Opal SM, Laterre PF, Francois B, LaRosa SP, Angus DC, Mira JP, Wittebole X, Dugernier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang CS, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent JL; ACCESS Study Group. Opal SM, et al. Among authors: francois b. JAMA. 2013 Mar 20;309(11):1154-62. doi: 10.1001/jama.2013.2194. JAMA. 2013. PMID: 23512062 Clinical Trial.
Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR, Francois B, Mira JP, Vincent JL, Dellinger RP, Russell JA, Larosa SP, Laterre PF, Levy MM, Dankner W, Schmitt N, Lindemann J, Wittebole X. Bernard GR, et al. Among authors: francois b. Crit Care Med. 2014 Mar;42(3):504-11. doi: 10.1097/CCM.0000000000000043. Crit Care Med. 2014. PMID: 24335445 Clinical Trial.
Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit.
Vincent JL, Marshall JC, Namendys-Silva SA, François B, Martin-Loeches I, Lipman J, Reinhart K, Antonelli M, Pickkers P, Njimi H, Jimenez E, Sakr Y; ICON investigators. Vincent JL, et al. Among authors: francois b. Lancet Respir Med. 2014 May;2(5):380-6. doi: 10.1016/S2213-2600(14)70061-X. Epub 2014 Apr 14. Lancet Respir Med. 2014. PMID: 24740011 Free article.
668 results